A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx (®) in advanced breast cancer

PURPOSE: To compare the pharmacokinetic (PK) bioequivalence (BE) and safety of a generic pegylated liposomal doxorubicin (PLD) formulation with the reference product Caelyx(®). METHODS: A multicenter, single-dose, open-label, randomized, two-way crossover study was conducted in patients with breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yinjuan, Qi, Lu, Wang, Yu, Li, Yan, Lei, Chunpu, Zhang, Yingjuan, Cheng, Xiaoqiang, Liu, Ju, Bai, HaiHong, Zhao, Xia, Lv, Shuzhen, Xiong, Bingjun, Liu, Juan, Shi, Yehui, Zhou, Huan, Li, Hongtao, Liu, Lihong, Jiang, Hongchuan, Ouyang, Weiwei, Li, Xiaowen, Li, Yanping, Wang, Xinghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810385/
https://www.ncbi.nlm.nih.gov/pubmed/36605440
http://dx.doi.org/10.3389/fonc.2022.1070001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810385/
https://www.ncbi.nlm.nih.gov/pubmed/36605440
http://dx.doi.org/10.3389/fonc.2022.1070001

Ejemplares similares